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Abstract
Oxidative stress is believed to cause endothelial dysfunction, an early event and a hallmark in cardiovascular diseases (CVD)
including hypertension, diabetes, and dyslipidemia. However, the targets for oxidative stress-mediated endothelial
dysfunction in CVD have not been completely elucidated. Here we report that 26S proteasome activation by peroxynitrite
(ONOO
2) is a common pathway for endothelial dysfunction in mouse models of diabetes, hypertension, and dyslipidemia.
Endothelial function, assayed by acetylcholine-induced vasorelaxation, was impaired in parallel with significantly increased
26S proteasome activity in aortic homogenates from streptozotocin (STZ)-induced type I diabetic mice, angiotensin-infused
hypertensive mice, and high fat-diets -fed LDL receptor knockout (LDLr
2/2) mice. The elevated 26S proteasome activities
were accompanied by ONOO
2-mediated PA700/S10B nitration and increased 26S proteasome assembly and caused
accelerated degradation of molecules (such as GTPCH I and thioredoxin) essential to endothelial homeostasis.
Pharmacological (administration of MG132) or genetic inhibition (siRNA knockdown of PA700/S10B) of the 26S proteasome
blocked the degradation of the vascular protective molecules and ablated endothelial dysfunction induced by diabetes,
hypertension, and western diet feeding. Taken together, these results suggest that 26S proteasome activation by ONOO
2-
induced PA700/S10B tyrosine nitration is a common route for endothelial dysfunction seen in mouse models of
hypertension, diabetes, and dyslipidemia.
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Introduction
Peroxynitrite (ONOO
2) is formed by the reaction of superoxide
anions with nitric oxide (NO) at diffusion-controlled rate. It
represents a crucial pathogenic mechanism in CVD when
excessively produced [1,2]. Among many chemical reactions,
ONOO
2 is well known by its impact on proteins through tyrosine
nitration and leaving its footprint as 3-nitrotyrosine [2]. Many
studies have elegantly demonstrated endogenous ONOO
2
generation and its diverse downstream targets, such as lipids,
DNA, and proteins [2], in CVD. Although the roles of ONOO
2
in the pathogenesis of endothelial dysfunction and atherosclerosis
have been well established, the protein targets of ONOO
2 in
CVD have been largely unidentified.
The ubiquitin proteasome system (UPS) functions as the major
non-lysosomal intracellular proteolytic system responsible for
degradation of most proteins, particularly those of short-lived
and regulatory nature [3]. The essential role of this system includes
control of protein quality, cell cycle, transcription factor regu-
lation, gene expression, cell differentiation, and immune response
[4]. Degradation of proteins by the UPS occurs in two steps,
including targeting of proteins and successive degradation by the
26S proteasome, the major proteolysis complex in the system. The
26S proteasome is a multi-catalytic protease consisting of a 20S
catalytic core and two 19S regulatory particles (PA700) [4]. PA700
is first characterized as an ATP-dependent 20S proteasome
activator for 26S proteasome activation [5]. Later, sub-complexes
of PA700 important for substrate selection and processing have
also been identified [6,7]. Regardless modes of action, increasing
evidence demonstrate that PA700 is crucial in functional
regulation of the UPS [8]. Alterations in UPS have been shown
to contribute to the pathogenesis of cancer, neurodegenerative,
and immune diseases [9]. An emerging role has been implicated in
the pathogenesis of atherosclerosis [10].
Endothelial dysfunction, defined by impaired endothelium-
dependent relaxation, is an early marker for atherosclerosis. Many
of the risk factors such as diabetes, hypertension, and dyslipidemia
that predispose to atherosclerosis can also cause endothelial
dysfunction, and the presence of multiple risk factors has been
found to predict endothelial dysfunction. Available data suggest
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e29649that oxidant stress-activated 26S proteasome mediated endothelial
dysfunction in streptozotocin-induced diabetic mice [11] and
angiotensin II (Ang II) induced hypertensive mice [12], as well as
in experimental hypercholesterolemia pig [13]. It remained to be
established if oxidative stress-activated 26S proteasomes is an early
and a common pathogenic phenomenon for cardiovascular risk
factors and cardiovascular diseases (CVD). Here we report that
ONOO
2 tyrosine nitrates PA700/S10B resulting in activation of
26S proteasome and consequent endothelial dysfunction in mouse
models of diabetes, hypertension and dyslipidemia.
Materials and Methods
Materials
Mouse GTPCH I antibody was purchased from Ascenion
GmBH (Munich, Germany); ubiquitin antibody from Santa Cruz
Biotechnology (Santa Cruz, CA); mouse PA700/S10B antibody
from Abcam (Cambridge, MA); MG132 and purified 26S
proteasome from BioMol (Plymouth Meeting, PA); fluorogenic
proteasome substrates from Calbiochem (San Diego, CA);
tetrahydro-L-biopterin dihydrochloride (BH4) from Cayman
(Ann Arbor, MI). HUVECs and HMVEC were obtained from
Cascade Biologics (Walkersville, MD) and ScienCell (Carlsbad,
CA), respectively. Human GTPCH I antibody was kindly
provided by Dr. Gabriele Werner-Felmayer (Innsbruck Medical
University, Austria). All the other antibodies and reagents,
including angiotensin II (Ang II) and streptozotocin (STZ), were
obtained from Santa Cruz Biotechnology (Santa Cruz, CA) or
Fisher Scientific (Pittsburgh, PA).
Mice
Ten-week-old male C57BL/6J mice and low density lipoprotein
receptor knockout (LDLr
2/2) mice were obtained from the
Jackson Laboratory (Bar Harbor, Me). Mice were housed in
temperature controlled cages with a 12-hour light/dark cycle and
given free access to water and chow. The mice were euthanized
with inhaled isoflurane at the end of the animal experiments.
Aortas were then removed for endothelial function assay or
immediately frozen in liquid nitrogen for other assays. The animal
protocols for models of diabetes, hypertension and dyslipidemia
used in this paper were reviewed and approved by the Institutional
Animal Care and Use Committee at the University of Oklahoma
Health Sciences Center. The approved IACUC protocol numbers
are: 10-153-H, 11-072-H and 11-045.
Assays of the 26S proteasome activity
26S proteasome activity was assayed by measuring ATP
dependent degradation of proteasome fluorescence substrate, as
described previously [11,14].
Streptozotocin-induced diabetes mellitus in mice
A low-dose of STZ induction regimen was used to induce
pancreatic islet cell destruction and persistent hyperglycemia as
described by the Animal Models of Diabetic Complications
Figure 1. ONOO
2 nitrates PA700/S10B and increases 26S proteasome activity both in vitro and in intact cell. In vitro (A–C): ONOO
2
(1 mM) was incubated with the purified 26S proteasome for 5 min; in intact cell (D–E): HUVEC was incubated with ONOO
2 for 0.5 h, in the presence or
absence of uric acid (50 mM pre-incubation for 1 h). Cell free system (in vitro) was subjected to (A) Western blot to detect levels of PA700/S10B and
the tyrosine nitration of 26S proteasome/PA700/S10B, (B) 26S proteasome activity (chymotrypsin-like activity), (C) an alternative 26S proteasome
activity assay: a substrate-in-gel assay with a fluorogenic substrate followed by fluorescence capturing under the UV light. HUVEC cell lysate was
subjected to (D) Western blotting of PA700/S10B tyrosine nitration and (E) assay of 26S proteasome activity (chymotrypsin-like activity). All blots
shown are representative of three independent experiments. All results (n=3) were analyzed with a one-way ANOVA.
doi:10.1371/journal.pone.0029649.g001
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as a random blood glucose level of .450 mg/dL for .2 weeks
after injection. One additional group of STZ mice received
Tempol (Sigma; 1 mmol/L) in their drinking water for an
additional 2 weeks. Aortas were all harvested 3 weeks after STZ
injection.
Ang II-induced hypertension and blood pressure
measurement
Ang II was continuously administered in 10-week-old C57BL/
6J mice (Jackson Laboratory, Bar Harbor, ME) at a rate of
0.8 mg/kg/d for 14 days using a mini-osmotic pump (AlzetH)a s
previously reported [15]. Arterial blood pressure was determined
using a carotid catheter method as previously described [16]. High
blood pressure (hypertension) was defined and achieved as
previously reported [16]. Transfection with siRNA was performed
as previously described [16].
LDLr
2/2 dyslipidemia model
The LDLr
2/2 mice were fed a Western diet or high fat diet
(HFD) containing 0.21% cholesterol and 21% fat (Research Diets
Inc, D12079B) for 8 weeks. Two weeks after HFD, an MG132
osmotic pump (delivered at rate of 0.72 mg/kg per day;
DURECT Corporation, Model 2006) or the inhibitor-diluents
(DMSO), as a negative control, was implanted subcutaneously in
LDLr
2/2 or the control WT mice for 6 weeks. Dyslipidemia was
defined as previously reported [17].
Assays of endothelium-dependent and endothelium-
independent vasorelaxation
Vessel Aortic rings isolated from the treated mice were
subjected to organ chamber assay of endothelium-dependent
and -independent vasodilatation as described previously [11].
Statistical analysis
Comparison of vasodilatation or data from other experiments
involving more than two factors (such as endothelial dependent
vessel relaxation assay) was performed with a two-way ANOVA,
and intergroup differences were determined using the Bonferroni
inequality method. All other results were analyzed with a one-way
ANOVA. Values are expressed as mean 6 SEM. P,0.05 was
accepted as significant.
Results
Exogenous ONOO
2 increase PA700 tyrosine nitration
and 26S proteasome activity in vitro
To test the impacts of ONOO
2 on the 26S proteasome,
purified 26S proteasomes were exposed to low concentration
(1 mM) of chemically synthesized ONOO
2 in vitro. As depicted in
Fig. 1, ONOO
2 markedly increased 3-nitrotyrosine staining of
PA700/S10B, the regulatory unit of 26S proteasome, without
changing the apparent integrity of the proteasome (Fig. 1A). The
increment of tyrosine nitration in PA700/S10B was correlated
with an over 2-fold increase in 26S proteasome activity (Fig. 1B).
Increased 26S proteasome activity was further confirmed by an in
situ substrate-in-gel assay, in which the vehicle- or ONOO
2 -
treated 26S proteasomes were separated on a native-PAGE
(3–14% gradient gel) followed by fluorogenic substrate incubation
and fluorescence capturing under UV (Fig. 1C: in-gel substrate).
ONOO
2 nitrates PA700/S10B and increases 26S
proteasome activity in intact endothelial cells
We next investigated if the effects of ONOO
2 on proteasome
activity could be recapitulated in HUVEC. As depicted in
Figure 1D, exogenous addition of ONOO
2 in HUVEC
significantly enhanced tyrosine nitration of PA700/S10B
Figure 2. ONOO
2 promotes 26S proteasome assembly both in vitro and in intact cell. In vitro (A): ONOO
2 (1 mM) was incubated with the
purified 26S proteasome for 5 min; in intact cell (B): HUVEC was incubated with ONOO
2 for 0.5 h, in the presence or absence of uric acid (50 mM pre-
incubation for 1 h). Cell free system (in vitro) was subjected to (A) separation on a native gradient (3–14%) PAGE gel followed either by Western-
blotting (IB) or a direct staining with coomassie brilliant blue (CBB staining) for 26S proteasome assembly. HUVEC cell lysate was subjected to (B)
Western blotting of the PA700/S10B co-immunoprecipitates with a b7 antibody. All blots shown are representative of three independent
experiments. All results (n=3) were analyzed with a one-way ANOVA.
doi:10.1371/journal.pone.0029649.g002
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(UA), a known ONOO
2 scavenger, abolished the ONOO-
enhanced PA700/S10B tyrosine nitration (Fig. 1D). Further, UA
abrogated ONOO
2 enhanced proteasome activation in HUVEC
(Fig. 1E). In sum, these data suggest that exogenous ONOO
2
causes tyrosine nitration of PA700/S10B resulting in consequent
activation of 26S proteasome in HUVEC.
ONOO
2 enhances 26S proteasome assembly in vitro and
in intact endothelial cells
The assembly of 19S and 20S proteasomes into 26S proteasome
is considered as a key step in controlling 26S proteasome activity
[5]. Thus, it was interesting to evaluate if ONOO
2 increased the
assembly of 19S and 26S proteasome sub-complexes. We first
tested this on the purified proteasomes. We used native PAGE gel
to separate the treated 26S proteasomes, like Fig. 1C, and then
either performed a Western blotting (Fig. 2A: IB) or a direct
staining with Coomassie Brilliant Blue (CBB) (Fig. 2A: CBB
staining). Compared to the vehicle-treated (Fig. 2A), ONOO
2-
treated 26S proteasomes presented an increase in PA700/S10B IB
staining as well as the 26S proteasome CBB staining, suggesting an
increased 26S proteasome assembly (Fig. 2A: IB and CBB
staining), which may contribute to the enhanced 26S proteasome
activity (Fig. 1B and 1C).
We further tested if the ONOO
2-mediated 26S proteasome
assembly could be reproduced in intact cells. To avoid the
confound effects exerted by the proteasome purification and
enrichment which is required in the native gel approach, we
adapted a previously described approach [12] by measuring the
association of proteasome representative subunits to estimate 26S
proteasome assembly. These subunits represent the19S (PA700/
S10B) and the 20S (b7) sub-complex, respectively. As shown in
Fig. 2B, ONOO
2 increased 26S proteasome assembly, as evi-
denced by increased association of PA700/S10B and b7 subunits,
compared to those treated with the vehicle. Pre-incubation of uric
acid abrogated ONOO
2-enhanced proteasome association in
HUVEC (Fig. 2B). Collectively, these data suggest that exogenous
ONOO
2 promotes 26S proteasome assembly in intact cell.
The 26S proteasome is activated in aortic homogenates
from mouse models of diabetes, hypertension, and
dyslipidemia
We sought to exploit if ONOO
2-mediated 26S proteasome
activation could be recapitulated in whole animals when
cardiovascular risk factors were present. We first assayed 26S
proteasome activity in mouse model of STZ-induced diabetes, Ang
II-induced hypertension, and HFD induced dyslipidemia, which
are all recognized cardiovascular risk factors and associated with
Figure 3. The 26S proteasome is activated and results in degradation of the target proteins, which can be prevented either by
ONOO
2 inhibition or by MG132 administration, in aortic homogenates from mouse models of diabetes, hypertension, and
dyslipidemia. Mouse models of (A) diabetes (STZ: 50 mg/kg/d, sham: sodium citrate, i.p., 5d; MG132, 5 mg/kg/d, i.p., 2d; n=5/group); (B)
hypertension (angiotensin II: 0.8 mg/kg/d, sham: saline; osmotic pump infusion, 14d.; PA700/S10B/control siRNA, i.v. 7d; n=5/group) and (C) high fat-
diets-induced atherosclerosis (LDLr
2/2 mice, normal chow or HFD, 8 wks; MG132: 0.8 mg/kg/d; sham: saline; osmotic pump infusion, 2 wks after
HFD, 6 wks; n=5/group). AT the end of the animal experiment, aortas were removed and their homogenates were either subjected to 26S
proteasome activity assay (chymotrypsin-like activity) (A–C), or Western blotting with the corresponding antibodies as indicated. All results (n=5)
were analyzed with a one-way ANOVA. * indicates significant vs. control; NS: not significant vs. control.
doi:10.1371/journal.pone.0029649.g003
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diabetic aorta presented a ,2 fold increase in 26S proteasome
activity compared to those of the vehicle-treated control mice
(Fig. 3A). Injection of a potent proteasome inhibitor MG132
(5 mg/kg body weight, i.p. 2d., as reported [11,18]) significantly
decreased 26S proteasome activity in STZ-induced diabetic mice
(Fig. 3A). In aortic preparation from Ang II-infused hypertensive
mice, about 2-fold of increase in 26S proteasome activity were
detected (Fig. 3B); however, knockdown of PA700/S10B, which
were confirmed in Fig. 4B, suppressed the 26S proteasome
activation (Fig. 3B). Similarly, compared to normal chow fed mice,
aortic tissues prepared from HFD fed mice (dyslipidemia)
presented approximately 2 fold increase in 26S proteasome
activity (Fig. 3C); the enhanced 26S proteasome activation was
blocked when MG132 was administrated (through the implanted
osmotic pump with infusion rate of 0.72 mg/kg/d, 6 wks, as
reported [19]) (Fig. 3C).
Pharmacologic or genetic inhibition of 26S proteasome
prevents GTPCH I and thioredoxin from degradation in
mouse models of diabetes, hypertension, and
dyslipidemia
We next exploited the functional outcomes of the altered 26S
proteasome activity by examining the turnover of proteins that are
essential to endothelial cell homeostasis and are recognized
substrates of or related to the 26S proteasome. GTP cyclohy-
drolase I (GTPCH I) is one of the very few known proteins in this
category. As a potential substrate of the 26S proteasome
[11,20,21,22]_ENREF_23, GTPCH I is a rate limiting enzyme
for de novo synthesis of tetrahydrobioptin (BH4), a key cofactor of
eNOS [23]. Indeed, aortas from diabetic (Fig. 3D), hypertensive
(Fig. 3E) mice, but not the control mice, presented decreased
GTPCH I levels, as we previously reported [11,12]. Interestingly,
protein levels of GTPCH I were also found decreased in aortic
tissues from the HFD-induced dyslipidemia mice, compared to
normal chow fed mice (Fig. 3F). Furthermore, protein levels of
thioredoxin (Trx), a protein important to maintain a cellular
reducing environment [24,25], was also decreased in aortas from
the mice of diabetes (Fig. 3D), hypertension (Fig. 3E), and
dyslipidemia (Fig. 3F). Importantly, inhibition of ONOO
2
generation by Tempol administration (Fig. 3D), or inhibition of
the 26S proteasome by siRNA-mediated PA700/S10B knockdown
(Fig. 3E), or by MG132 treatment, restored protein levels of both
GTPCH I and Trx (Fig. 3D, 3E, and 3F).
Enhanced PA700/S10B tyrosine nitration and 26S
proteasome assembly in mouse models of diabetes,
hypertension, and dyslipidemia
We then investigate the potential mechanisms underlying 26S
proteasome activation which would be shared by all studied
models. To this end, we used an anti-PA700/S10B antibody to
pull down PA700/S10B so that the levels of nitrated PA700/S10B
could be assessed with an anti-nitrotyrosine antibody in Western
blot. As shown in Fig. 4A, compared to those of vehicle-treated
Figure 4. PA700/S10B tyrosine nitration and 26S proteasome sub-complex association (assembly), but not the PA700/S10B protein
levels, are increased in aortic homogenates from mouse models of diabetes, hypertension, and dyslipidemia. Mouse models of (A)
diabetes (STZ: 50 mg/kg/d, sham: sodium citrate, i.p., 5d; Tempol, 1 mmol/kg/drinking water, 2 wks.; n=5/group); (B) hypertension (angiotensin II:
0.8 mg/kg/d, sham: saline; osmotic pump infusion, 14d.; PA700/S10B/control siRNA, i.v. 7d; n=5/group) and (C) high fat-diets-induced dyslipidemia
(LDLr
2/2 mice, normal chow or HFD, 8 wks; MG132: 0.8 mg/kg/d; sham: saline; osmotic pump infusion, 2 wks after HFD and for 6 wks; n=5/group).
AT the end of the animal experiment, aortas were removed and their homogenates were subjected to immunoprecipitation and Western blot. The
immunoprecipitation assay was performed using either an anti-PA700/S10B or anti-3-NT antibody. All blots shown are representative for mice n=5.
All results were analyzed with a one-way ANOVA. * indicates significant vs. control; NS: not significant vs. control.
doi:10.1371/journal.pone.0029649.g004
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PA700/S10B tyrosine nitration, accompanied by enhanced 26S
assembly, as evidenced by increased association of 26S proteasome
sub-complexes (PA700/S10B, the 19S proteasome sub-complex
and the 20S proteasome core), but not PA700/S10B protein levels
(Fig. 4A). Importantly, these augments were abolished in mice
treated with Tempol, a potent superoxide scavenger therefore an
inhibitor of ONOO
2 generation (Fig. 4A).
Like the effect of STZ-induced diabetes, Ang II also increased
PA700/S10B tyrosine nitration and 26S proteasome assembly, but
not PA700/S10B protein levels (Fig. 4B), consistent with our
previous studies [12]. Furthermore, siRNA-mediated PA700/
S10B knockdown prevented association of 26S proteasome sub-
complexes as expected (Fig. 4B). Such a loss of 26S proteasome
assembly was in line with the blockage of Ang II-induced 26S
proteasome activation (Fig. 2B) and of the reduction of GTPCH I
and Trx protein levels (Fig. 3B).
Importantly, HFD, but not the normal chow feeding, elevated
both PA700/S10B tyrosine nitration and 26S proteasome
assembly (Fig. 4C). Interestingly, MG132 infusion for 6 weeks
reversed these increase, without affecting PA700/S10B protein
levels (Fig. 4C). Of note, the levels of PA700/S10B tyrosine
nitration and 26S proteasome assembly were closely related to
those of the 26S proteasome activity (Fig. 3C).
Nitration of PA700/S10B-mediated 26S proteasome
induces endothelial dysfunction
Finally, we monitored the endothelial function of isolated vessel,
a valuable surrogate endpoint to assess the impact of therapeutic
interventions [26]. As presented in Fig. 5, aortas from diabetic but
not control mice, exhibited impaired acetylcholine-induced vessel
relaxation (Fig. 5A) in parallel with a down-regulation of both
GTPCH I and Trx proteins (Fig. 3D), which were associated with
enhanced PA700/S10B tyrosine nitration, 26S proteasome
assembly (Fig. 4A) and activation (Fig. 3A). However, these effects
were abolished when Tempol, a SOD mimetic, was co-
administrated (Fig. 3D, 4A, and 5A), a reminiscence of the
protective effect of MG132 administration previously observed
[11]. In contrast, aortas from all group of mice presented no
significant differences in vessel relaxation evoked by sodium
nitroprusside (SNP) (Fig. 5B), an NO donor that can induce
endothelium-independent vessel relaxation [27]. This indicates
that the impairment of acetylcholine-induced vessel relaxation is
mainly due to endothelial dysfunction.
Similarly, aortas from the mice of Ang II-induced hypertension
(Fig. 5C) and of HFD-induced dyslipidemia (Fig. 5D) shared the
same pathway, manifesting as an impaired acetylcholine-induced
vessel relaxation (Fig. 5C and 5D) which were associated the
PA700/S10B-mediated 26S proteasome activation (Fig. 3B, 3C,
Figure 5. Inhibition of the 26S proteasome either by ONOO
2 inhibition or by MG132 administration rescues endothelial
dysfunction in mouse models of diabetes, hypertension, and dyslipidemia. Mouse models of (A/B) diabetes (STZ: 50 mg/kg/d, sham:
sodium citrate, i.p., 5d; Tempol, 1 mmol/kg/drinking water, 2 wks.; n=5/group); (C/E) hypertension (angiotensin II: 0.8 mg/kg/d, sham: saline; osmotic
pump infusion, 14d.; PA700/S10B/control siRNA, i.v. 7d; n=5/group) and (D/F) high fat-diets-induced dyslipidemia (LDLr
2/2 mice, normal chow or
HFD, 8 wks; MG132: 0.8 mg/kg/d; sham: saline; osmotic pump infusion, 2 wks after HFD and for 6 wks; n=5/group). AT the end of the animal
experiment, aortas were removed for endothelial function assay. The removed aortas were cut into 3-mm rings, and precontracted with 30 nmol/L of
U46619 in organ chambers (PowerLab, ADInstruments, Colorado Springs, Co). (A/C/D) Endothelium-dependent vasodilator responses were
determined in the presence of acetylcholine (0.01 to 100 mmol/L). (B/E/F) Endothelium-independent vasodilator responses were determined in the
presence of sodium nitroprusside (SNP) (0.0001 to 1 mmol/L). All results were analyzed with a one-way ANOVA. * indicates significant v.s. control; NS:
not significant v.s. control.
doi:10.1371/journal.pone.0029649.g005
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either by siRNA-mediated PA700/S10B knockdown (Fig. 5C) or
by MG132 administration (Fig. 5D) significantly ameliorated the
acetylcholine-induced vessel relaxation. Likewise, there were no
significant differences in SNP-evoked vessel relaxation among
groups (Fig. 5E and 5F), further indicating that endothelial
dysfunction contributes to the impaired vessel relaxation.
Discussion
In this study, we have defined a mechanism shared by different
models of cardiovascular diseases, in which tyrosine nitration of
PA700/S10B- mediated 26S proteasome deregulation is linked to
endothelial dysfunction, a key surrogate marker for CVD. To the
best of our knowledge, this is the first report on the impacts of
oxidative stress on a major subcellular system in multiple animal
models with risk factors of cardiovascular disease. Proteasome
deregulation could alter essential cellular targets, resulting in
diseased conditions (Fig. 6). Therefore, the current study will open
new avenue to proteasome-related mechanisms in CVD.
In supporting the notion that oxidative stress links 26S pro-
teasome activation to endothelial dysfunction, we have provided
evidence at various setting ranging from cell free and cell culture to
whole animal models with common CVD risk factors. In
highlights, we found that (1) ONOO
2 reacts directly with the
isolated 26S proteasome, which results in increased 26S protea-
some assembly and activation, likely through the enhanced
tyrosine nitration of PA700/S10B, the key regulatory complex of
26S proteasomes; (2) such a ONOO
2-mediated biochemical
process occurs in intact culture cells, because pretreatment of the
culture cells with UA, a ONOO
2 scavenger, prevents the 26S
proteasome activation pathway; (3) independent of the type of
CVD risk factors in the studied models, aortic 26S proteasome
activation are all present; (4) the 26S proteasome activation in
animal study manifests as the increased 26S proteasome assembly
and activity, which are all accompanied by augmented PA700/
S10B tyrosine nitration; (5) activation of aortic 26S proteasome
decreases proteins which are important to endothelial homeostasis;
such as GTPCH I, which is directly related to NO bioavailability
and key to the vascular endothelial function, and Trx, which is
related to endothelial function maintenance [24] through reactive
oxygen species scavenging [28], apoptosis suppression [29], or
survival promotion [30]; (6) intervention through ONOO
2
inhibition (Tempol administration) or through 26S proteasome
inhibition, via pharmaceutical (MG132 administration) or genetic
approaches (siRNA knockdown of PA700/S10B), restore GTPCH
I and Trx, the proteins that have been shown important for
endothelial homeostasis; (7) these data are further validated in vivo
in that either inhibition of endogenous ONOO
2 or 26S pro-
teasome activation could ameliorate the otherwise impaired
endothelial function (restoration of acetylcholine-induced vessel
relaxation). Emerging data support that proteasome assembly,
including 26S complex assembly [6,31,32] and individual
sub-complex assembly [33,34], is important for its function.
Post-translational modifications of PA700 have been linked to the
regulation of proteasome assembly [35] and function [36],
although it remains to be established how tyrosine nitration
observed in present study would affect the assembly. Therefore,
the increased 26S assembly, induced by oxidative stress (e.g.
ONOO
2) mediated proteasome modifications (e.g. tyrosine
nitration), is likely the mechanism for deregulated 26S proteasome,
which is linked to endothelial dysfunction shared by the studied
mouse models.
A cardinal feature of endothelial dysfunction is impaired
endothelium-dependent vasodilatation caused by loss of NO
bioavailability [37]. Not a single mechanism alone can explain
endothelial dysfunction. Rather, an interplay among multiple
regulatory pathways results in pathogenesis of this vascular
disorder [38,39,40]. Oxidant such as ONOO
2 attacks various
molecules in vascular endothelium, vascular smooth muscle and
myocardium, eventually leading to endothelial dysfunction in
CVD [2]. In the present study, GTPCH I degradation is
attributed to ONOO
2 activated 26S proteasome in several
models. However, we did not exclude the possibility that ONOO
2
also makes it a good substrate for proteasome, since mild
modification by ONOO
2 results in selective recognition and
degradation by proteasome [41]. In either case, activated 26S
proteasome would accelerate GTPCH I degradation. It is crucial
to maintain appropriate levels of GTPCH I protein for vascular
health, since GTPCH I deficiency has been demonstrated in
animal models to cause endothelial dysfunction [11] and high
blood pressure [16]. In contrast, restoration of GTPCH I has been
found beneficial [42], which is due, at least in part, to the
improved endothelial function [42,43] or the suppression of
Figure 6. Tyrosine nitration of PA700/S10B-mediated protea-
some activation is a common pathway leading to endothelial
dysfunction in mouse models with cardiovascular risk factors.
Oxidative stress plays an essential role in the parthenogenesis of
cardiovascular diseases including diabetes, hypertension and dyslipide-
mia. ONOO
2, formed by the reaction of superoxide with nitric oxide at
diffusion-controlled rate, when overproduced, has been demonstrated
to affect various pathophysiological events. The presented evidence
support a shared mechanism in mouse models with cardiovascular risk
factors, in which deregulation of 26S proteasome caused by ONOO
2,
likely via tyrosine nitration of PA700/S10B, the regulatory complex of
26S proteasomes. Proteasome deregulation could alter essential cellular
targets, resulting in early diseased conditions, such as endothelial
dysfunction (the initial damaging stage), which may either adaptively
improve or worsen the conditions (arrows). Identification of mecha-
nisms underlying these alterations may help to define proper
intervention to bring clinic benefit to the patients.
doi:10.1371/journal.pone.0029649.g006
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for redox regulation, such as Trx, are in the list of the proteasome
substrates in the present study. These proteins have been shown to
be endothelial function protective. For instance, the predominant
role of Trx to limit oxidative stress directly has been demonstrated
in various disease models [45]. Although we presented limited
target proteins as evidence of functional proteasome activation, we
expect other key molecules may undergo the same pathway which
warrants further investigation. In fact, increasing evidence revels
that UPS involves in the turn-over of eNOS [46,47,48,49], one of
the most endothelial protective molecule, and several other factors
essential to endothelium homeostasis [50]. It is widely believed
that imbalance between the generation of endothelial-derived
relaxing factors (EDFR) and contracting factors (EDCF) may
contribute to endothelial dysfunction [51]. Therefore, it would be
important to examine if UPS also affects the turnover of these
factors globally, an under-examined dimension of proteomics in
protein stability in humans [52]. It is also important to note that
global activation of 26S proteasome does not guarantee target
degradation, a complex process that may require additional
(co)factors. However, given the fact that PA700/S10B siRNA
knockdown abolishes the effects mediated by proteasomes, 26S
proteasome activation does play a decisive role in the degradation
of its substrates. In any case, the observed activation of 26S
proteasome may be one of the crucial partners for the whole
degradation process. It merits further investigation to identify new
partners in this unified mechanism.
In summary, the preclinical data presented here indicate that
oxidative stress (ONOO
2) might be the common linker that
connects 26S proteasome activation to endothelial dysfunction,
which is prevalent in most types of CVD. Although targets of
ONOO
2 vary [2]_ENREF_2, manipulating the shared one as
demonstrated in this study may bring overall beneficial clinic
outcome. The findings in this study also may provide insight to drug
design for CVD in that targeting specific components of the 26S
proteasome might improve the outcomes of medical intervention.
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